Please try another search
For the nine months ended 30 September 2018, Keryx Biopharmaceuticals revenues increased 80% to $75.5M. Net loss before extraordinary items decreased 54% to $61M. Revenues reflect Net U.S. Auryxia product sales increase of 87% to $71.3M, License revenue increase of 13% to $4.2M. Lower net loss reflects Amortization of debt discount decrease of 94% to $3.5M (expense).
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Revenue | 28.04 | 25.75 | 21.75 | 18.68 |
Gross Profit | 19.66 | 17.33 | 11.47 | 10.4 |
Operating Income | -14.69 | -20.15 | -22.75 | -31.01 |
Net Income | -17 | -21.52 | -21.9 | -30.43 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Assets | 151.78 | 145.65 | 140.12 | 158.87 |
Total Liabilities | 206 | 186.84 | 171.73 | 172.97 |
Total Equity | -54.22 | -41.19 | -31.61 | -14.1 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Period Length: | 9 Months | 0 Months | 3 Months | 0 Months |
Cash From Operating Activities | -78.18 | -54.79 | -33.43 | -93.49 |
Cash From Investing Activities | -0.05 | -0.05 | -0.08 | -1.26 |
Cash From Financing Activities | 25.85 | 10.78 | 0.07 | 76.46 |
Net Change in Cash | -52.38 | -44.07 | -33.44 | -18.28 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review